Strides Arcolab receives USFDA nod for blood cancer injection

NEW DELHI: Drug firm Strides Arcolab on Monday said its subsidiary Onco Therapies has received approval from the US health regulator to market its generic Cladribine injection used for treating blood cancer in the American market.

" Onco Therapies Ltd, a wholly-owned subsidiary ...has received USFDA approval for Cladribine injection 1 mg/ ML packaged in 10 mg/ 10 mL single dose vials," Strides Arcolab said in a statement.

The product is expected to be launched shortly, it added. "Cladribine is part of the oncology portfolio licensed to Pfizer in January 2010 for the US market," the company said.

The company claimed that according to the IMS data, the US market for generic cladribine is approximately USD 5.3 million.

Cladribine is used to treat a type of blood cancer known as 'hairy cell leukaemia'.

Shares of Strides Arcolab today closed at Rs 343.40 on the BSE, up 0.37 per cent from the previous close.